VIATRIS INC. Business Combination, Contingent Consideration, Liability, Current
VIATRIS INC. (VTRS) had Business Combination, Contingent Consideration, Liability, Current of $18.90 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent · last filed 2026-08-06
- 2026-06-30: Business Combination, Contingent Consideration, Liability, Current $18.90M.
- 2026-03-31: Business Combination, Contingent Consideration, Liability, Current $27.70M.
- 2025-12-31: Business Combination, Contingent Consideration, Liability, Current $28.50M.
- 2025-09-30: Business Combination, Contingent Consideration, Liability, Current $36.90M.
| Period end | Business Combination, Contingent Consideration, Liability, Current |
|---|---|
| 2026-06-30 | $18.90M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $27.70M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $28.50M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $36.90M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $37.10M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $44.70M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $59.50M 10-K · filed 2026-02-26 |
| 2024-09-30 | $49.80M 10-Q · filed 2024-11-07 |
| 2023-12-31 | $76.10M 10-K · filed 2026-02-26 |
| 2022-12-31 | $64.40M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |